Goldman Sachs’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.8M | Buy |
883,560
+142,954
| +19% | +$1.91M | ﹤0.01% | 2151 |
|
|
2025
Q1 | $7.55M | Buy |
740,606
+205,022
| +38% | +$2.09M | ﹤0.01% | 2429 |
|
|
2024
Q4 | $8.48M | Buy |
535,584
+179,920
| +51% | +$2.85M | ﹤0.01% | 2462 |
|
|
2024
Q3 | $20.7M | Sell |
355,664
-165,783
| -32% | -$9.63M | ﹤0.01% | 1721 |
|
|
2024
Q2 | $23.8M | Buy |
521,447
+263,079
| +102% | +$12M | ﹤0.01% | 1471 |
|
|
2024
Q1 | $17.1M | Buy |
258,368
+53,269
| +26% | +$3.53M | ﹤0.01% | 1658 |
|
|
2023
Q4 | $8.15M | Buy |
205,099
+105,040
| +105% | +$4.18M | ﹤0.01% | 2236 |
|
|
2023
Q3 | $3.19M | Buy |
100,059
+26,152
| +35% | +$834K | ﹤0.01% | 2789 |
|
|
2023
Q2 | $2.97M | Buy |
73,907
+11,647
| +19% | +$468K | ﹤0.01% | 2941 |
|
|
2023
Q1 | $2.66M | Sell |
62,260
-83,562
| -57% | -$3.57M | ﹤0.01% | 3011 |
|
|
2022
Q4 | $7M | Sell |
145,822
-30,542
| -17% | -$1.47M | ﹤0.01% | 2380 |
|
|
2022
Q3 | $6.64M | Buy |
176,364
+28,513
| +19% | +$1.07M | ﹤0.01% | 2440 |
|
|
2022
Q2 | $4.09M | Buy |
147,851
+20,020
| +16% | +$553K | ﹤0.01% | 2834 |
|
|
2022
Q1 | $6.95M | Buy |
127,831
+8,533
| +7% | +$464K | ﹤0.01% | 2536 |
|
|
2021
Q4 | $6.98M | Buy |
119,298
+67,389
| +130% | +$3.94M | ﹤0.01% | 2551 |
|
|
2021
Q3 | $2.05M | Buy |
51,909
+29,439
| +131% | +$1.16M | ﹤0.01% | 3466 |
|
|
2021
Q2 | $954K | Buy |
22,470
+16,108
| +253% | +$684K | ﹤0.01% | 4048 |
|
|
2021
Q1 | $392K | Sell |
6,362
-117,553
| -95% | -$7.24M | ﹤0.01% | 4500 |
|
|
2020
Q4 | $8.74M | Buy |
123,915
+106,197
| +599% | +$7.49M | ﹤0.01% | 2136 |
|
|
2020
Q3 | $683K | Buy |
+17,718
| New | +$683K | ﹤0.01% | 3510 |
|